On one hand, a study published by Meggendorfer et al., demonstrated a significantly shorter overall survival (OS) in patients harboring both alterations compared with MDS-5q patients without SF3B1 mutation [35]. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.